Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 142

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 142
---
 goals.

The study demonstrated that
JOTROL™ achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner,
MCI/Early Alzheimer’s Disease trial and Yui et al., Friedreich’s ataxia trial). The results of this Phase 1 study were published
in the Journal of Alzheimer’s diseases and AAPS Open in February 2022. The results from this study will be used as a cross-reference
for all indications where JOTROL™ will be used in Phase II and Phase III clinical trials. The Company has not discussed
the use of cross-referencing in this manner with the FDA or other comparable regulatory authorities.

JOTROL™Intellectual Property and License Agreement

We hold an exclusive global
license dated from Aquanova for micellar technologies to develop, manufacture, and sell JOTRO on the terms set forth in the license agreement.
Our CSO, Marshall Hayward, and Aquanova’s lead scientist, Darius Benham, invented JOTROL™. The patent is co-owned
by Aquanova and us, with the application assigned to Aquanova. Filed in Germany on January 29, 2017, the patent (PCT/EP2017/O51659) expires
in 2036 and is granted in the USA, Japan, China, Hong Kong, and specific European countries. The patent covers a solubilization product
with resveratrol, polysorbate 80 and 20, MCT, and tocopherols for pharmaceutical use. It includes claims on formulation specifics, micelle
size, turbidity, and treatment applications for diseases like Alzheimer’s and diabetes. The product is available in various capsule
forms and is administered orally.

Our license agreement with
Aquanova is vital, as JOTROL™ is our primary product. Losing this agreement would delay our plans and force us to seek similar
licenses, if available, adversely affecting our business. The agreement grants us worldwide exclusivity to utilize granted and pending
patents. Effective from September 15, 2016, it lasts until patent expiration or ten years after the first commercial sale. We paid an
upfront fee of $20,000 and an annual license fee of $75,000 until the first product approval. Milestone payments of $200,000 are due
per territory upon regulatory approval, with royalties set at 5% of net sales. Each party has the option, within 180 days of a